Review on sodium glucose co-transporter-2 inhibitors for treatment of type-2 diabetes mellitus

Sodium glucose transporter-2 inhibitors (SGLT2-i) are a class of medicine that have been recently acknowledged and approved for management Type-2 Diabetes Mellitus (T2DM). They distinct encouraging extra-pancreatic glucuretic role has clinically applied blood sugar management. Reports published multiple side effects including ketoacidosis & ketonuria induced by SGLT2-i. This endeavor delves into the pharmacokinetics SGLT-i agents, deliberates utility these drugs suggests steps to maximize safe use agents their diverse beneficial effects.